Meta-analysis of double-expressor lymphoma prognoses and novel therapies
Double-expressor lymphoma linked to worse survival outcomes in large study
This systematic evaluation meta-analysis of 9,808 patients with diffuse large B-cell lymphoma found double-expressor lymphoma (DEL) is assoc…
A major review finds double-expressor lymphoma patients have worse survival. New drug combinations show promise for better results.
Tucidinostat plus R-CHOP improves outcomes in MYC/BCL2 double-expressor DLBCL
New drug tucidinostat improves outcomes for high-risk lymphoma patients
A phase 3 trial found adding oral tucidinostat to R-CHOP significantly improved event-free survival and complete response rates in patients …
A large trial shows adding tucidinostat to standard chemo lowers disease risk and improves survival for patients with aggressive lymphoma.
FDA Approves Xpovio (selinexor) for Multiple Myeloma and DLBCL
FDA approves new drug Xpovio for certain blood cancers.
The FDA approved Xpovio (selinexor) for multiple myeloma in combination with bortezomib and dexamethasone after at least one prior therapy, …
The FDA approved Xpovio (selinexor) for multiple myeloma and a type of lymphoma called DLBCL. It offers a new option for patients who have t…
Mecapegfilgrastim reduces grade 3+ neutropenia in treatment-naive diffuse large B-cell lymphoma patients versus no prophylaxis
New Drug Cuts Severe Infection Risk In Lymphoma Care
This randomized controlled trial evaluated mecapegfilgrastim in 42 treatment-naive patients with diffuse large B-cell lymphoma.
A new long-acting injection lowers the risk of dangerous low white blood cell counts in lymphoma patients starting their first round of chem…
Eight-gene signature associated with survival in patients with Diffuse Large B-cell lymphoma
Doctors find a new way to predict who needs stronger cancer care sooner
In this cohort study, a predictive signature based on the reactivation of eight normally silent tissue-dependent genes was identified in pat…
A new blood test can spot dangerous lymphoma risks early so doctors can change treatment plans before patients get sicker.
High FGR protein expression associated with worse relapse-free survival in de novo DLBCL patients treated with R-CHOP
New Protein Test Predicts Lymphoma Relapse Risk
This retrospective cohort study evaluated 91 patients with de novo diffuse large B-cell lymphoma treated with R-CHOP.
A new protein test identifies diffuse large B-cell lymphoma patients at high risk of relapse before treatment fails, giving doctors a crucia…
High-dose pegylated liposomal doxorubicin shows comparable survival to conventional doxorubicin in DLBCL with reduced toxicity
A Gentler Chemo Version Holds Its Own in Lymphoma
A retrospective cohort of 512 DLBCL patients found comparable 2-year PFS (74.3% vs.
A gentler chemo drug wrapped in fat bubbles matched standard treatment for lymphoma survival while sharply cutting serious side effects like…
Phase 2 trial compares Inotuzumab Ozogamicin plus R-CVP for DLBCL patients unfit for anthracycline
Can a new drug combination help lymphoma patients who can't take standard chemo?
A Phase 2 interventional trial enrolled 129 patients with diffuse large B-cell lymphoma (DLBCL) who were unsuitable for anthracycline-contai…
A new drug combo aims to treat aggressive lymphoma in older patients who can't take standard chemo due to heart risks.
Case report describes treatment response in rare dual-lesion DLBCL with heterogeneous subtypes
Doctors describe treatment response in rare case of dual-lesion lymphoma
A case report and systematic review describes a 65-year-old female with rare dual-lesion DLBCL featuring both GCB and ABC subtypes.
Doctors treated a woman with two different rare lymphoma types in her brain and muscle, achieving stability after adjusting her chemotherapy…
Case report describes management of Burkitt's lymphoma with concurrent HIV, CMV encephalitis, and salmonella bacteremia
Case report describes complex treatment for man with lymphoma, HIV, and infections
A case report describes a 50-year-old man with newly diagnosed HIV, stage IV Burkitt's lymphoma with CNS and marrow involvement, CMV viremia…
Doctors managed a 50-year-old man with newly diagnosed HIV, aggressive lymphoma, and multiple serious infections through coordinated care fr…